Century Therapeutics (IPSC) CEO and director reports 52,000-share buy

Rhea-AI Filing Summary

Century Therapeutics, Inc. reported an insider transaction by a director who also serves as President and CEO. On 12/12/2025, this person acquired 52,000 shares of common stock in a transaction coded “P” at a weighted average price of $0.5837 per share.

After this purchase, the insider beneficially owns 3,322,990 common shares with direct ownership. The filing notes that the shares were bought in multiple trades between $0.577 and $0.5838 per share, and that all profits from the reported transactions will be disgorged to the company under applicable requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pfeiffenberger Brent

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		P(1)		52,000	A	$0.5837(2)	3,322,990	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All profits from the reported transactions will be disgorged to the issuer pursuant to applicable requirements.

2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.577 to $0.5838. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

	/s/ Douglas Carr, Attorney-in-Fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Century Therapeutics (IPSC) report?

The filing reports that a director and officer, who serves as President and CEO of Century Therapeutics, Inc. acquired 52,000 shares of the company’s common stock.

When did the IPSC insider transaction occur?

The earliest transaction date reported for the insider purchase of Century Therapeutics (IPSC) common stock is 12/12/2025.

How many Century Therapeutics (IPSC) shares did the insider buy and at what price?

The insider purchased 52,000 shares of Century Therapeutics common stock at a weighted average price of $0.5837 per share, through multiple trades.

How many IPSC shares does the insider own after this transaction?

Following the reported transaction, the insider beneficially owns 3,322,990 shares of Century Therapeutics (IPSC) common stock, held with direct ownership.

Over what price range were the Century Therapeutics (IPSC) shares purchased?

According to the filing, the 52,000 shares were bought in multiple transactions at prices ranging from $0.577 to $0.5838 per share.

What does the filing say about profits from the IPSC insider transactions?

The filing states that all profits from the reported transactions will be disgorged to the issuer pursuant to applicable requirements.

What is the relationship of the reporting person to Century Therapeutics (IPSC)?

The reporting person is listed as both a Director and an Officer, with the title President and CEO of Century Therapeutics, Inc.